4

Back to all posts

First Results From Field Study Of RenoVō® Equine Allograft Released
Renovo Horse Background

Equine Amnio Solutions, LLC (EAS), a distributor of advanced, next-generation regenerative products derived from amniotic birth tissues, announced today first results from a large field study of RenoVō® for soft tissue and orthopedic horse injuries.

RenoVō® is an acellular, cryopreserved liquid allograft derived from equine amniotic tissues and is intended for equine use. Amniotic birth tissues are rich sources of bioactive factors involved in tissue regeneration with reported anti-inflammatory, anti-bacterial and anti-fibrotic properties. Donors are healthy mares and tissues are collected without harm to the mare or foal. RenoVō® is manufactured by Equus Innovations (Phoenix, Arizona) and has been used in over 2000 horses to date.

The study, entitled “A prospective case series investigating the outcome of horses with soft tissue and orthopedic injuries using RenoVō®” was led by Principal Investigators Brent Hague, DVM, DACVS and Mike Schoonover, DVM, MS, DACVS-LA, DACVSMR in partnership with the Oklahoma State University College of Veterinary Medicine.

Criterion for inclusion was lameness attributed to tendonitis and desmitis by diagnostic anesthesia and/or imaging, resulting in 100 subjects with 128 lesions. Horses were treated by perilesional administration of RenoVō® by the attending veterinarian with a minimum of six months follow-up.

Investigators concluded that use of this liquid amnion allograft for treatment of various tendon or ligament injuries offered comparable, or superior, outcomes to those reported in studies using various other regenerative medicine modalities. Overall, 72% of horses were reported to have returned to, or exceeded, their previous level of work. The product was also noted to have the distinct advantage of being readily available, requiring no preparation, processing or delay in treatment and a favorable adverse event profile. Attending veterinarians for 92% of the horses reported satisfaction with RenoVō® and response to therapy. The associated manuscript for these results is currently in preparation. Data on subjects with orthopedic joint injuries will be released separately.

Christian Beaudry, MBA, CTBS, DABRM and Equus Innovations’ Chief Operating and Scientific Officer stated, “These first study results provide compelling evidence for the product as a safe and efficacious option for the equine practitioner. We believe the results further establish RenoVō® as a superior alternative to other modalities in the clinical management of equine soft tissue injury.”

About Equine Amnio Solutions

Equine Amnio Solutions, LLC (EAS) is the market leader in the distribution of next-generation regenerative veterinary products including RenoVō®. Equine Amnio Solutions works closely with its product manufacturer, Equus Innovations (Phoenix, Arizona). Our mission is to provide innovative products to maximize the health and performance of horses across all breeds and athletic disciplines.

About Oklahoma State University College of Veterinary Medicine

OSU’s College of Veterinary Medicine is one of 30 veterinary colleges in the United States and the only veterinary college in Oklahoma. For more information, visit https://vetmed.okstate.edu.

RenoVō® is a Registered Trademark of Equine Amnio Solutions, LLC.

You may want to read these articles

RenoVō® CASE STUDY: Puncture Wound

RenoVō® CASE STUDY: Puncture Wound

Case presentation - June 9, 2022: A three-year-old Quarter Horse filly backed into the catch for the stall door and punctured herself, creating a large, deep wound on her left thigh. The wound was sutured with internal and external stiches at clinic, however the...

RenoVō® CASE STUDY: Superficial Digital Flexor Tendon (RH)

RenoVō® CASE STUDY: Superficial Digital Flexor Tendon (RH)

Case presentation - June 9, 2016: A 9 year old Warmblood jumping horse presented with a superficial digital flexor tendon injury of the right hind leg. The horse was treated with stem cell injections. After 10 months of rest and rehabilitation, the horse slowly went...

RenoVō® CASE STUDY: Summer Sore

RenoVō® CASE STUDY: Summer Sore

Case presentation - June 17, 2022: A 19-year-old Red Horse presented to Topgun Veterinarian Service, Rock Hill, SC, with a large Summer Sore on the commissure of the right side of the mouth. The horse was treated orally with Ivermectin and topically with Ivermectin...